Project Grant SB1AG087748
Award Date
9/20/24
Completion Date
5/31/26
Dollars Obligated
$3.4M
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Connecticut, USA
Similar Awards
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Transchromix LLC for $994,436 supports the development of a novel, brain-penetrant drug targeting the histone methyltransferase G9A for the treatment of Alzheimer's disease. The project aims to elucidate the mechanism of action for the drug candidate MS1262, which has been shown to reverse Alzheimer's-related protein expression and restore cognitive and affective functions in a mouse model....
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,883 to Degrome Therapeutics, Inc. to develop small-molecule degraders of the amyloid precursor protein (APP) as novel therapeutics for Alzheimer's disease (AD). The project aims to optimize lead APP degrader compounds to improve their potency, solubility, and blood-brain barrier permeability, with the goal of identifying the most promising candidates for further development and evaluation...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,432,649 to Virogenics, Inc., a biotechnology company in San Diego, California, to advance the development of CMS121, an innovative drug candidate for the treatment of Alzheimer's disease (AD). The funding will support two key components: 1) A 13-week toxicology study in rats and dogs to enable longer-term clinical trials of CMS121 in human subjects with mild to moderate AD, and 2) The...
This $1,041,646 federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) supports the early clinical development of modified P8 (MP8), a novel peptide drug candidate for the treatment of Alzheimer's disease. The grant recipient, Cenna Biosciences Inc., aims to conduct activities to support a first-in-human clinical study of MP8, including chemistry, manufacturing, and controls (CMC) work, a pre-IND meeting with the FDA, IND application submission,...
This $500,000 Project Grant was awarded on September 15, 2024 by the National Institute on Aging (CFDA 93.866 Aging Research program) to Neucyte Inc., a minority-owned small business specializing in advanced biomedical research and development. The funding will support the development of a miniaturized "mini-brain" microphysiological system (MPS) platform using Alzheimer's disease (AD) patient-derived cells. The goal is to create a scalable, reproducible in vitro brain model that can...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,998.00 to Encue Inc., a small disadvantaged business located in Evanston, IL, to develop novel small molecule modulators of synaptic plasticity for the treatment of Alzheimer's disease (AD)-induced cognitive decline. The project aims to further develop the lead molecule JB2 as a therapeutic to reverse or delay the onset of cognitive dysfunction in AD by restoring normal expression...
The National Institute on Aging (NIA) awarded a $295,000 Project Grant under the Aging Research program (CFDA 93.866) to Florida International University (FIU). The 2-year award, effective from September 15, 2024 to August 31, 2026, aims to develop a novel biotherapeutic nanogel system to target key biomarkers of Alzheimer's disease (AD). The proposed nanogels are designed to enhance blood-brain barrier penetration, inhibit amyloid-beta aggregation, and mitigate oxidative stress and...
The National Institute on Aging (NIA) awarded a $349,605 Project Grant under the Aging Research program (CFDA 93.866) to Stress Therapeutics, Inc. to advance the development of a novel therapeutic candidate for the long-term management of Alzheimer's disease (AD) and other conditions characterized by excessive activation of the hypothalamic-pituitary-adrenal (HPA) axis. The Phase I SBIR grant project aims to optimize a lead candidate therapeutic that can reduce HPA hyperactivity, a key...
This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,441 to Acepre, LLC to develop a novel brain-targeted delivery system for the compound N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The key objectives of this Phase I STTR study are to: 1) evaluate the toxicity and pharmacokinetic properties of TN-NAC in mice, and 2) test the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model of...